Figure 2. Oral Administration of pazopanib causes regression of choroidal neovascularization (CNV).

Four week old C57BL/6 mice had laser photocoagulation-induced rupture of Bruch’s membrane at 3 locations in each eye and after 7 days 5 mice were perfused with fluorescein-labeled dextran and the baseline area of CNV was measured by image analysis. The remaining mice were treated twice a day by oral gavage with vehicle (9 mice) or 4 (7 mice), 20 (7 mice), or 100 mg/kg of pazopanib (8 mice). After 7 days, the area of CNV at Bruch’s membrane rupture sites was measured. The bars represent the mean (±SEM) area of CNV at laser sites where rupture of Bruch’s membrane was achieved (n=28, 54, 40, 35, and 48 for baseline, vehicle, 4 mg, 20 mg, and 100 mg, respectively). The area of CNV in eyes treated twice a day with 4 mg/kg of pazopanib was similar to that seen at baseline and significantly less than that seen in eyes treated with vehicle, suggesting that growth of CNV had been suppressed. The area of CNV in eyes of mice treated twice a day with 20 or 100 mg/kg of pazopanib was significantly less than the baseline area indicating that regression of CNV had occurred.

*p<0.0001; **p=0.0013 by linear mixed model with Dunnett’s correction for multiple comparisons.